Currently in Preclinical stage, the Debio 0228 ([177Lu]Lu-DPI-4452) program is set to identify a Development Candidate with best-in-class potential, designed to selectively destroy tumor cells that express the CAIX target. The selected compound will be developed using a theranostic approach, a combination of diagnostic and therapeutic features with the same compound, allowing the pre-identification of patients who have the receptors necessary to respond to the targeted radiotherapy.
Focus on the mode of action
Debio 0228 is a new generation, targeted radiopharmaceutical using a theranostic approach. This includes a combination of diagnostic and therapeutic features with the same compound, allowing the pre-identification of patients who have the receptors necessary to respond to treatment. Potential responders are qualified for their personalized therapy via diagnostic molecular imaging evaluating target expression in their tumor lesions, allowing only those patients who might potentially benefit from receiving the radiotherapy. The therapeutic ligand attaches to the specific surface receptors, releasing the radiation to destroy the tumor from the inside.